Patent Assignment
Reel/Frame 045788/0148
Release of Security Interest
Recorded: 2018-03-30
Pages: 82
Assignor
BLACK HORSE CAPITAL MASTER FUND LTD.
Executed: 2018-03-15
Assignee
KALOBIOS PHARAMECUTICALS, INC.
1000 MARINA BLVD, #250, BRISBANE, CALIFORNIA, 94005-1878
Covered Properties
(38)
Receptor-Ligand System and Assay
Patent:
7,037,662 →
Application:
09/104,340 →
Circularly Permutated, Interaction-Activated Proteins
Method of and Compositions for Immunization with the Pseudomonas V Antigen
Reactivation-Based Molecular Interaction Sensors
Chimerized Gm-Csf Antibodies
Method and Compositions for Immunization with the Pseudomonas V Antigen
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
Application:
10/544,701 →
Publication:
US 2006/0140957
Transactivation system for mammalian cells
Methods for Affinity Maturation
Antibody Specificity Transfer Using Minimal Essential Binding Determinants
Secretion of Antibodies Without Signal Peptides from Bacteria
Humanized Gm-Csf Antibodies
EphA3 Antibodies for the Treatment of Solid Tumors
Antibodies to the Pcrv Antigen of Pseudomonas Aeruginosa
Method and Compositions for Immunization with the Pseudomonas V Antigen
Methods of Treating Heart Failure Using an Anti-Gm-Csf Antibody
Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
Combination Antibiotic and Antibody Therapy for the Treatment of Pseudomonas Aeruginosa Infection
Application:
12/700,599 →
Publication:
US 2010/0272736
Methods of Treating Dementia Using a Gm-Csf Antagonist
Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
Antibodies to EPHA3
Method of Treating a Staphylococcus Infection in a Patient Having a Low-Level Pathogenic Pseudomonas Aeruginosa Infection
EPHA3 Antibodies for the Treatment of Multiple Myeloma
Application:
13/078,747 →
Publication:
US 2011/0243934
Generation of Antibodies to an Epitope of Interest
Application:
13/079,641 →
Publication:
US 2011/0245100
Detection of EPHA3 as a Marker of the Presence of a Solid Tumor
Application:
13/164,581 →
Publication:
US 2011/0318304
Methods of Treating Bone-Loss Disorders Using a Gm-Csf Antagonist
Application:
13/179,304 →
Publication:
US 2012/0009191
Antibodies to the Pcrv Antigen of Pseudomonas Aeruginosa
Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
Anti-EMR1 Antibodies
Secretion of antibodies without signal peptides from bacteria
Methods of Treating Hematological Proliferative Disorders by Targeting EPHA3 Expressed on Aberrant Vasculature in Bone Marrow
Generation of Antibodies to an Epitope of Interest That Contains a Phosphomimetic Amino Acid
Application:
13/644,353 →
Publication:
US 2013/0109586
Antibodies to EPHA3
Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EPHA3
Application:
14/473,821 →
Publication:
US 2014/0370010
Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
Application:
14/677,604 →
Publication:
US 2015/0344565
Methods of Treating Chronic Inflammatory Diseases Using a Gm-Csf Antagonist
Application:
14/712,627 →
Publication:
US 2015/0246121
Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow
Application:
14/814,179 →
Publication:
US 2015/0329647
Immunoglobulin Variable Region Cassette Exchange
Related Assignments
(13)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 3, 2009
From: FRANK, DARA W.; YAHR, TIMOTHY L.; FRITZ, ROBERT B.
To: MCW RESEARCH FOUNDATION
Reel/Frame 023599/0915 →
Assignment of Assignor's Interest
May 18, 2012
From: BEBBINGTON, CHRISTPHER R.; YU, BO
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 028237/0096 →
Security Interest
May 23, 2016
From: KALOBIOS PHARMACEUTICALS, INC.
To: BLACK HORSE CAPITAL, LP
Reel/Frame 038788/0266 →
Security Interest
Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →
Change of Name
Nov 6, 2017
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 044377/0915 →
Change of Name
Nov 6, 2017
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 044767/0814 →
Release of Security Interest
Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
Corrective Assignment to Correct the Statement of Federally Sponsored Research or Development Previously Recorded on Reel 000020 Frame 20. Assignor(S) Hereby Confirms the This Invention Was Made with Us Government Support Awarded by Nih Grant Numbers AI001289, AI031665, and HL059239.
Jan 2, 2019
From: MEDICAL COLLEGE OF WISCONSIN
To: MEDICAL COLLEGE OF WISCONSIN
Reel/Frame 047999/0920 →
Security Interest
Jul 16, 2019
From: HUMANIGEN, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 049769/0067 →
Change of Name
May 15, 2020
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 052679/0552 →
Change of Name
Jun 5, 2020
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 052858/0975 →
Release of Security Interest
Jun 12, 2020
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: HUMANIGEN, INC.
Reel/Frame 052920/0631 →
Confirmatory License
Oct 8, 2020
From: MEDICAL COLLEGE OF WISCONSIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054032/0981 →